S- Editor Zhu LH L- Editor Zhu LH E- Editor Zhou T
Published online Mar 28, 2007. doi: 10.3748/wjg.v13.i12.1767
Revised: March 9, 2006
Accepted: March 12, 2007
Published online: March 28, 2007
Colorectal cancer (CRC) is caused by a series of genetic or epigenetic changes, and in the last decade there has been an increased awareness that there are multiple forms of colorectal cancer that develop through different pathways. Microsatellite instability is involved in the genesis of about 15% of sporadic colorectal cancers and most of hereditary nonpolyposis cancers. Tumors with a high frequency of microsatellite instability tend to be diploid, to possess a mucinous histology, and to have a surrounding lymphoid reaction. They are more prevalent in the proximal colon and have a fast pass from polyp to cancer. Nevertheless, they are associated with longer survival than stage-matched tumors with microsatellite stability. Resistance of colorectal cancers with a high frequency of microsatellite instability to 5-fluorouracil-based chemotherapy is well established. Silencing the MLH1 gene expression by its promoter methylation stops the formation of MLH1 protein, and prevents the normal activation of the DNA repair gene. This is an important cause for genomic instability and cell proliferation to the point of colorectal cancer formation. Better knowledge of this process will have a huge impact on colorectal cancer management, prevention, treatment and prognosis.
- Citation: Niv Y. Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer. World J Gastroenterol 2007; 13(12): 1767-1769
- URL: https://www.wjgnet.com/1007-9327/full/v13/i12/1767.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i12.1767
Colorectal cancer (CRC) is caused by a series of genetic or epigenetic changes, and in the last decade there has been an increased awareness that there are multiple forms of CRC that develop through different pathways. The common mechanism (more than 50% of sporadic CRCs) is that of chromosomal instability (CIN)[1-3]. The second pathway (35% of sporadic CRCs) is caused by epigenetic inactivation of tumor suppressor genes. Because of the mechanism involved in this, it is called the CpG island methylator phenotype (CIMP). A third pathway is caused by failure of the DNA mismatch repair system, and these tumors have a characteristic signature mutation called microsatellite instability (MSI), MSI-high (MSI-H), MSI-low (MSI-L) or MSI-stable (MSS). Recently, Jass classified CRCs according to CpG island methylator phenotype and MSI status into 5 new types: (1) CIMP-high, MSI-H, BRAF mutation; (2) CIMP-high, MSI-L or MSS, BRAF mutation; (3) CIMP-low, MSS or MSI-L, KRAS mutation; (4) CIMP-negative, MSS; (5) CIMP-negative, MSI-H (Lynch Syndrome). There were clinical, morphological and prognostic factors characteristic of every type, thus Jess concluded that this approach will have a tremendous impact on management, prevention and treatment of CRC.
Microsatellite instability is involved in the genesis of about 15% of sporadic CRCs and most of hereditary nonpolyposis CRCs (HNPCC)[5-7]. The multiple errors in repetitive DNA sequences (microsatellites) result from a failure of the DNA mismatch repair (MMR) system to edit errors made during DNA replication. The DNA MMR system is inactivated either by hypermethylation of the promoter, which silences gene transcription of hMLH1 (epigenetic phenomenon; sporadic CRC), or because of germ-like mutations in MMR genes MLH1, MSH2, MSH6 and others (genetic phenomenon, HNPCC)[9,10]. Recently, Hitchins and colleagues described an inheritance of a cancer-associated MLH1 germ-line epimutation. They found evidence that MLH1 promoter hypermethylation of one allele was transmitted from a mother to her son but was erased in his spermatozoa, thus the allele had reverted to the normal active state.
Tumors with a high frequency of MSI-H tend to be diploid, to possess a mucinous histology, and to have a surrounding lymphoid reaction. They are more prevalent in the proximal colon and have a fast pass from polyp to cancer. Nevertheless, they are associated with longer survival than stage-matched MSI-L tumors or MSS tumors[12-18]. It is still unclear if this favorable prognosis is attributable to the inherently lower aggressiveness of MSI-H tumors or their greater sensitivity to chemotherapy other than 5-fluorouracil (5-FU).
Resistance of MSI-H CRC to 5-FU based chemotherapy is well established. A significant overall survival benefit was noted in patients with CRC who were treated with 5-FU based chemotherapy compared with those who were not. However, within the MSI-H group, there was no difference in survival by 5-FU treatment, whereas in the MSS group, the authors noted a significant difference in survival between patients given 5-FU and untreated patients. These findings indicate that the type of genomic instability within a colorectal tumor might dictate patient response to 5-FU based chemotherapy. Ribic and co-investigators used specimens from patients with stage II or III CRC who were previously enrolled in prospective, randomized trials of 5-FU based chemotherapy. Among the patients who had not received adjuvant chemotherapy, those with MSI-H tumors had longer overall survival and higher rates of 5-year disease-free survival than patients with MSI-L or MSS tumors. MSI-H status in patients who did not receive 5-FU based adjuvant chemotherapy was significantly associated with a better survival. However, among the group with MSI-H tumors, treatment was associated with a worse outcome for both stage II and III cancers.
Recently, an association between JC virus and CRC has been reported. The virus may act by stabilizing β-catenin, facilitating its entrance to the cell nucleus and triggering proliferation and cancer formation. Another possibility is initiation of hMLH1 methylation, since association between methylation and exposure to carcinogens such as viruses has been observed.
In summary, MLH1 promoter hypermethylation is an important event, silencing the MLH1 gene expression and preventing the formation of MLH1 protein and normal activation of the DNA repair gene. This induces genomic instability and cell proliferation to the point of CRC formation. Better knowledge of this process will have a significant impact on CRC management, prevention, treatment and prognosis.
|1.||Laghi L, Randolph AE, Chauhan DP, Marra G, Major EO, Neel JV, Boland CR. JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc Natl Acad Sci USA. 1999;96:7484-7489. [PubMed] [DOI]|
|2.||Ricciardiello L, Baglioni M, Giovannini C, Pariali M, Cenacchi G, Ripalti A, Landini MP, Sawa H, Nagashima K, Frisque RJ. Induction of chromosomal instability in colonic cells by the human polyomavirus JC virus. Cancer Res. 2003;63:7256-7262. [PubMed]|
|3.||Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007;132:127-138. [PubMed] [DOI]|
|4.||Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113-130. [PubMed] [DOI]|
|5.||Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558-561. [PubMed] [DOI]|
|6.||Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260:816-819. [PubMed] [DOI]|
|7.||Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, Järvinen H, Powell SM, Jen J, Hamilton SR. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812-816. [PubMed] [DOI]|
|8.||Carethers JM, Boland CR. Neoplasia of the gastrointestinal tract. Philadelphia: Lippincott-Raven 2003; 557-583.|
|9.||Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998;95:6870-6875. [PubMed] [DOI]|
|10.||Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA. 1998;95:8698-8702. [PubMed] [DOI]|
|11.||Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, Hawkins NJ, Ward RL. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med. 2007;356:697-705. [PubMed] [DOI]|
|12.||Lothe RA, Peltomäki P, Meling GI, Aaltonen LA, Nyström-Lahti M, Pylkkänen L, Heimdal K, Andersen TI, Møller P, Rognum TO. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res. 1993;53:5849-5852. [PubMed]|
|13.||Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69-77. [PubMed] [DOI]|
|14.||Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, Moon-Tasson L, Mahoney MR, Sargent DJ, O'Connell MJ. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst. 1999;91:1295-1303. [PubMed] [DOI]|
|15.||Lukish JR, Muro K, DeNobile J, Katz R, Williams J, Cruess DF, Drucker W, Kirsch I, Hamilton SR. Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg. 1998;227:51-56. [PubMed] [DOI]|
|16.||Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, White S, Bird CC, Wyllie AH. Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. Oncogene. 1996;12:2641-2649. [PubMed]|
|17.||Wright CM, Dent OF, Barker M, Newland RC, Chapuis PH, Bokey EL, Young JP, Leggett BA, Jass JR, Macdonald GA. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg. 2000;87:1197-1202. [PubMed] [DOI]|
|18.||Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N, Iacopetta B. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology. 2000;58:52-59. [PubMed] [DOI]|
|19.||Niv Y. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil. Isr Med Assoc J. 2005;7:520-524. [PubMed]|
|20.||Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-257. [PubMed] [DOI]|
|21.||Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248-5257. [PubMed]|
|22.||Niv Y, Goel A, Boland CR. JC virus and colorectal cancer: a possible trigger in the chromosomal instability pathways. Curr Opin Gastroenterol. 2005;21:85-89. [PubMed]|